[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ftk7IxbUnsnMsedsB40w-w9SPyZvbgb4XaKtaDaoXXPo":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":60,"rows":67},"University of Manchester",[4],200,false,43,4,705624,5,185,[14,17,20,23,26,28,30,32],{"name":15,"count":16},"Depression",11,{"name":18,"count":19},"Anxiety",9,{"name":21,"count":22},"Psychosis",8,{"name":24,"count":25},"Cancer",6,{"name":27,"count":11},"Stroke",{"name":29,"count":11},"Cardiovascular Diseases",{"name":31,"count":9},"Obesity",{"name":33,"count":9},"Dysphagia",[35,40,45,50,55],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT04201405","Gene Therapy with Modified Autologous Hematopoietic Stem Cells for Patients with Mucopolysaccharidosis Type IIIA","2024-10-30","Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT05425043","Granulocyte Transfusions After Umbilical Cord Blood Transplant","2026-06","Granulocytes",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT05665166","Gene Therapy With Modified Autologous Hematopoietic Stem Cells for Patients With Mucopolysaccharidosis Type II","2028-07","Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT07120776","Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial","2028-10","Camzyos",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT07372885","GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia","2028-12-31","Cord blood transplantation + conditioning + granulocytes of variable days according to study design",[61,62,63,64,65,66],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[68,97,119,139,163,184,212,230,260,278,296,324,342,367,392,417,446,464,482,511,529,547,572,599,617],{"intervention":59,"totalTrials":69,"cells":70},1,{"EARLY_PHASE1":71,"PHASE1":74,"PHASE2":76,"PHASE3":91,"PHASE4":93,"NA":95},{"trials":72,"activeCount":73},[],0,{"trials":75,"activeCount":73},[],{"trials":77,"activeCount":69,"soonestReadout":58},[78],{"nctId":56,"briefTitle":57,"status":79,"phases":80,"primaryCompletion":58,"completion":81,"start":82,"enrollment":83,"conditions":84,"interventions":90},"NOT_YET_RECRUITING",[62,63],"2029-12-31","2026-02-09",50,[85,86,87,88,89],"Acute Myeloid Leukemia","Stem Cell Transplantation","Stem Cell Transplantation, Hematopoietic","Cord Blood Stem Cell Transplantation","Cellular Therapy",[59],{"trials":92,"activeCount":73},[],{"trials":94,"activeCount":73},[],{"trials":96,"activeCount":73},[],{"intervention":39,"totalTrials":69,"cells":98},{"EARLY_PHASE1":99,"PHASE1":101,"PHASE2":103,"PHASE3":113,"PHASE4":115,"NA":117},{"trials":100,"activeCount":73},[],{"trials":102,"activeCount":73},[],{"trials":104,"activeCount":69,"soonestReadout":38},[105],{"nctId":36,"briefTitle":37,"status":106,"phases":107,"primaryCompletion":38,"completion":108,"start":109,"enrollment":11,"conditions":110,"interventions":112},"ACTIVE_NOT_RECRUITING",[62,63],"2026-10-30","2020-01-07",[111],"Mucopolysaccharidosis Type IIIA",[39],{"trials":114,"activeCount":73},[],{"trials":116,"activeCount":73},[],{"trials":118,"activeCount":73},[],{"intervention":49,"totalTrials":69,"cells":120},{"EARLY_PHASE1":121,"PHASE1":123,"PHASE2":125,"PHASE3":133,"PHASE4":135,"NA":137},{"trials":122,"activeCount":73},[],{"trials":124,"activeCount":73},[],{"trials":126,"activeCount":69,"soonestReadout":48},[127],{"nctId":46,"briefTitle":47,"status":106,"phases":128,"primaryCompletion":48,"completion":48,"start":129,"enrollment":11,"conditions":130,"interventions":132},[62,63],"2023-06-01",[131],"Mucopolysaccharidosis II",[49],{"trials":134,"activeCount":73},[],{"trials":136,"activeCount":73},[],{"trials":138,"activeCount":73},[],{"intervention":54,"totalTrials":69,"cells":140},{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":145,"PHASE3":147,"PHASE4":149,"NA":151},{"trials":142,"activeCount":73},[],{"trials":144,"activeCount":73},[],{"trials":146,"activeCount":73},[],{"trials":148,"activeCount":73},[],{"trials":150,"activeCount":73},[],{"trials":152,"activeCount":69,"soonestReadout":53},[153],{"nctId":51,"briefTitle":52,"status":154,"phases":155,"primaryCompletion":53,"completion":53,"start":156,"enrollment":157,"conditions":158,"interventions":162},"RECRUITING",[66],"2026-03-26",75,[159,160,161],"Hypertrophic Obstructive Cardiomyopathy \\(HOCM\\)","Left Ventricular Outflow Tract Obstruction","Myocardial Ischaemia",[54],{"intervention":44,"totalTrials":69,"cells":164},{"EARLY_PHASE1":165,"PHASE1":167,"PHASE2":169,"PHASE3":171,"PHASE4":173,"NA":175},{"trials":166,"activeCount":73},[],{"trials":168,"activeCount":73},[],{"trials":170,"activeCount":73},[],{"trials":172,"activeCount":73},[],{"trials":174,"activeCount":73},[],{"trials":176,"activeCount":69,"soonestReadout":43},[177],{"nctId":41,"briefTitle":42,"status":154,"phases":178,"primaryCompletion":43,"completion":43,"start":179,"enrollment":180,"conditions":181,"interventions":183},[66],"2021-09-14",40,[182],"Pediatric Cancer",[44],{"intervention":185,"totalTrials":69,"cells":186},"Sitagliptin",{"EARLY_PHASE1":187,"PHASE1":189,"PHASE2":191,"PHASE3":193,"PHASE4":195,"NA":210},{"trials":188,"activeCount":73},[],{"trials":190,"activeCount":73},[],{"trials":192,"activeCount":73},[],{"trials":194,"activeCount":73},[],{"trials":196,"activeCount":73},[197],{"nctId":198,"briefTitle":199,"status":200,"phases":201,"primaryCompletion":202,"completion":202,"start":203,"enrollment":204,"conditions":205,"interventions":208},"NCT00766441","Sitagliptin Versus Sulphonylurea in Type 2 Diabetes During Ramadan","TERMINATED",[65],"2009-10","2008-08",22,[206,207],"Diabetes","Hypoglycemia",[185,209],"sulphonylurea",{"trials":211,"activeCount":73},[],{"intervention":209,"totalTrials":69,"cells":213},{"EARLY_PHASE1":214,"PHASE1":216,"PHASE2":218,"PHASE3":220,"PHASE4":222,"NA":228},{"trials":215,"activeCount":73},[],{"trials":217,"activeCount":73},[],{"trials":219,"activeCount":73},[],{"trials":221,"activeCount":73},[],{"trials":223,"activeCount":73},[224],{"nctId":198,"briefTitle":199,"status":200,"phases":225,"primaryCompletion":202,"completion":202,"start":203,"enrollment":204,"conditions":226,"interventions":227},[65],[206,207],[185,209],{"trials":229,"activeCount":73},[],{"intervention":231,"totalTrials":69,"cells":232},"ketamine",{"EARLY_PHASE1":233,"PHASE1":235,"PHASE2":237,"PHASE3":239,"PHASE4":241,"NA":258},{"trials":234,"activeCount":73},[],{"trials":236,"activeCount":73},[],{"trials":238,"activeCount":73},[],{"trials":240,"activeCount":73},[],{"trials":242,"activeCount":73},[243],{"nctId":244,"briefTitle":245,"status":246,"phases":247,"primaryCompletion":248,"completion":249,"start":250,"enrollment":251,"conditions":252,"interventions":255},"NCT01140620","Effects of Ketamine and Risperidone on Cognition","COMPLETED",[65],"2010-11","2010-12","2010-06",87,[253,254],"Healthy Volunteers","Schizophrenia",[231,256,257],"risperidone","saline",{"trials":259,"activeCount":73},[],{"intervention":256,"totalTrials":69,"cells":261},{"EARLY_PHASE1":262,"PHASE1":264,"PHASE2":266,"PHASE3":268,"PHASE4":270,"NA":276},{"trials":263,"activeCount":73},[],{"trials":265,"activeCount":73},[],{"trials":267,"activeCount":73},[],{"trials":269,"activeCount":73},[],{"trials":271,"activeCount":73},[272],{"nctId":244,"briefTitle":245,"status":246,"phases":273,"primaryCompletion":248,"completion":249,"start":250,"enrollment":251,"conditions":274,"interventions":275},[65],[253,254],[231,256,257],{"trials":277,"activeCount":73},[],{"intervention":257,"totalTrials":69,"cells":279},{"EARLY_PHASE1":280,"PHASE1":282,"PHASE2":284,"PHASE3":286,"PHASE4":288,"NA":294},{"trials":281,"activeCount":73},[],{"trials":283,"activeCount":73},[],{"trials":285,"activeCount":73},[],{"trials":287,"activeCount":73},[],{"trials":289,"activeCount":73},[290],{"nctId":244,"briefTitle":245,"status":246,"phases":291,"primaryCompletion":248,"completion":249,"start":250,"enrollment":251,"conditions":292,"interventions":293},[65],[253,254],[231,256,257],{"trials":295,"activeCount":73},[],{"intervention":297,"totalTrials":69,"cells":298},"IL-1Ra",{"EARLY_PHASE1":299,"PHASE1":301,"PHASE2":303,"PHASE3":305,"PHASE4":320,"NA":322},{"trials":300,"activeCount":73},[],{"trials":302,"activeCount":73},[],{"trials":304,"activeCount":73},[],{"trials":306,"activeCount":73},[307],{"nctId":308,"briefTitle":309,"status":310,"phases":311,"primaryCompletion":312,"completion":313,"start":314,"enrollment":315,"conditions":316,"interventions":318},"NCT03249207","SC IL-1Ra in SAH - Phase III Trial (SCIL)","UNKNOWN",[64],"2024-04","2024-09","2018-10-11",612,[317],"Subarachnoid Hemorrhage",[297,319],"IL-1Ra Placebo",{"trials":321,"activeCount":73},[],{"trials":323,"activeCount":73},[],{"intervention":319,"totalTrials":69,"cells":325},{"EARLY_PHASE1":326,"PHASE1":328,"PHASE2":330,"PHASE3":332,"PHASE4":338,"NA":340},{"trials":327,"activeCount":73},[],{"trials":329,"activeCount":73},[],{"trials":331,"activeCount":73},[],{"trials":333,"activeCount":73},[334],{"nctId":308,"briefTitle":309,"status":310,"phases":335,"primaryCompletion":312,"completion":313,"start":314,"enrollment":315,"conditions":336,"interventions":337},[64],[317],[297,319],{"trials":339,"activeCount":73},[],{"trials":341,"activeCount":73},[],{"intervention":343,"totalTrials":69,"cells":344},"Minocycline",{"EARLY_PHASE1":345,"PHASE1":347,"PHASE2":349,"PHASE3":361,"PHASE4":363,"NA":365},{"trials":346,"activeCount":73},[],{"trials":348,"activeCount":73},[],{"trials":350,"activeCount":73},[351],{"nctId":352,"briefTitle":353,"status":246,"phases":354,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":360},"NCT02928965","The Benefit of Minocycline on Negative Symptoms in Schizophrenia: Extent and Mechanisms",[63],"2016-05","2013-02",207,[359],"Schizophrenia and Disorders With Psychotic Features",[343],{"trials":362,"activeCount":73},[],{"trials":364,"activeCount":73},[],{"trials":366,"activeCount":73},[],{"intervention":368,"totalTrials":69,"cells":369},"Anakinra 100Mg\u002F0.67Ml Inj Syringe",{"EARLY_PHASE1":370,"PHASE1":372,"PHASE2":374,"PHASE3":386,"PHASE4":388,"NA":390},{"trials":371,"activeCount":73},[],{"trials":373,"activeCount":73},[],{"trials":375,"activeCount":73},[376],{"nctId":377,"briefTitle":378,"status":200,"phases":379,"primaryCompletion":380,"completion":381,"start":382,"enrollment":11,"conditions":383,"interventions":385},"NCT04462757","SCIL-1Ra in COVID-19 Feasibility & PK\u002FPD",[63],"2020-08-31","2020-12-23","2020-05-28",[384],"COVID-19",[368],{"trials":387,"activeCount":73},[],{"trials":389,"activeCount":73},[],{"trials":391,"activeCount":73},[],{"intervention":393,"totalTrials":69,"cells":394},"Baricitinib",{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":411,"PHASE4":413,"NA":415},{"trials":396,"activeCount":73},[],{"trials":398,"activeCount":73},[],{"trials":400,"activeCount":73},[401],{"nctId":402,"briefTitle":403,"status":246,"phases":404,"primaryCompletion":405,"completion":405,"start":406,"enrollment":407,"conditions":408,"interventions":410},"NCT04208464","JAK 1\u002F2 Inhibitor, Baricitinib, in the Treatment of Adult IIM",[63],"2023-09-25","2021-10-07",15,[409],"Idiopathic Inflammatory Myopathies",[393,393],{"trials":412,"activeCount":73},[],{"trials":414,"activeCount":73},[],{"trials":416,"activeCount":73},[],{"intervention":418,"totalTrials":69,"cells":419},"Paclitaxel",{"EARLY_PHASE1":420,"PHASE1":422,"PHASE2":424,"PHASE3":440,"PHASE4":442,"NA":444},{"trials":421,"activeCount":73},[],{"trials":423,"activeCount":73},[],{"trials":425,"activeCount":73},[426],{"nctId":427,"briefTitle":428,"status":310,"phases":429,"primaryCompletion":430,"completion":431,"start":432,"enrollment":433,"conditions":434,"interventions":437},"NCT03570437","Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?",[63],"2023-01-31","2023-06-30","2018-05-17",124,[435,436],"Carcinosarcoma","Endometrial Neoplasms",[418,438,439],"Cediranib","Olaparib",{"trials":441,"activeCount":73},[],{"trials":443,"activeCount":73},[],{"trials":445,"activeCount":73},[],{"intervention":438,"totalTrials":69,"cells":447},{"EARLY_PHASE1":448,"PHASE1":450,"PHASE2":452,"PHASE3":458,"PHASE4":460,"NA":462},{"trials":449,"activeCount":73},[],{"trials":451,"activeCount":73},[],{"trials":453,"activeCount":73},[454],{"nctId":427,"briefTitle":428,"status":310,"phases":455,"primaryCompletion":430,"completion":431,"start":432,"enrollment":433,"conditions":456,"interventions":457},[63],[435,436],[418,438,439],{"trials":459,"activeCount":73},[],{"trials":461,"activeCount":73},[],{"trials":463,"activeCount":73},[],{"intervention":439,"totalTrials":69,"cells":465},{"EARLY_PHASE1":466,"PHASE1":468,"PHASE2":470,"PHASE3":476,"PHASE4":478,"NA":480},{"trials":467,"activeCount":73},[],{"trials":469,"activeCount":73},[],{"trials":471,"activeCount":73},[472],{"nctId":427,"briefTitle":428,"status":310,"phases":473,"primaryCompletion":430,"completion":431,"start":432,"enrollment":433,"conditions":474,"interventions":475},[63],[435,436],[418,438,439],{"trials":477,"activeCount":73},[],{"trials":479,"activeCount":73},[],{"trials":481,"activeCount":73},[],{"intervention":483,"totalTrials":69,"cells":484},"Brufen retard",{"EARLY_PHASE1":485,"PHASE1":487,"PHASE2":489,"PHASE3":491,"PHASE4":493,"NA":495},{"trials":486,"activeCount":73},[],{"trials":488,"activeCount":73},[],{"trials":490,"activeCount":73},[],{"trials":492,"activeCount":73},[],{"trials":494,"activeCount":73},[],{"trials":496,"activeCount":73},[497],{"nctId":498,"briefTitle":499,"status":246,"phases":500,"primaryCompletion":501,"completion":502,"start":503,"enrollment":504,"conditions":505,"interventions":508},"NCT00895843","Protective Analgesia for Postoperative Pain Relief Following Day Case Oral Surgery",[66],"2007-12","2008-01","2006-11",122,[506,507],"Postoperative Pain","Wisdom Tooth",[483,509,510],"ibuprofen","Bupivacaine",{"intervention":509,"totalTrials":69,"cells":512},{"EARLY_PHASE1":513,"PHASE1":515,"PHASE2":517,"PHASE3":519,"PHASE4":521,"NA":523},{"trials":514,"activeCount":73},[],{"trials":516,"activeCount":73},[],{"trials":518,"activeCount":73},[],{"trials":520,"activeCount":73},[],{"trials":522,"activeCount":73},[],{"trials":524,"activeCount":73},[525],{"nctId":498,"briefTitle":499,"status":246,"phases":526,"primaryCompletion":501,"completion":502,"start":503,"enrollment":504,"conditions":527,"interventions":528},[66],[506,507],[483,509,510],{"intervention":510,"totalTrials":69,"cells":530},{"EARLY_PHASE1":531,"PHASE1":533,"PHASE2":535,"PHASE3":537,"PHASE4":539,"NA":541},{"trials":532,"activeCount":73},[],{"trials":534,"activeCount":73},[],{"trials":536,"activeCount":73},[],{"trials":538,"activeCount":73},[],{"trials":540,"activeCount":73},[],{"trials":542,"activeCount":73},[543],{"nctId":498,"briefTitle":499,"status":246,"phases":544,"primaryCompletion":501,"completion":502,"start":503,"enrollment":504,"conditions":545,"interventions":546},[66],[506,507],[483,509,510],{"intervention":548,"totalTrials":69,"cells":549},"Cardiovascular Agents, Other",{"EARLY_PHASE1":550,"PHASE1":552,"PHASE2":554,"PHASE3":556,"PHASE4":558,"NA":560},{"trials":551,"activeCount":73},[],{"trials":553,"activeCount":73},[],{"trials":555,"activeCount":73},[],{"trials":557,"activeCount":73},[],{"trials":559,"activeCount":73},[],{"trials":561,"activeCount":73},[562],{"nctId":563,"briefTitle":564,"status":310,"phases":565,"primaryCompletion":312,"completion":566,"start":567,"enrollment":568,"conditions":569,"interventions":571},"NCT05216913","Optimising Cardiovascular Health in Endometrial Cancer Survivors",[],"2024-10","2022-02-09",80,[570,29],"Endometrial Cancer",[548],{"intervention":573,"totalTrials":69,"cells":574},"Methotrexate",{"EARLY_PHASE1":575,"PHASE1":577,"PHASE2":579,"PHASE3":581,"PHASE4":583,"NA":585},{"trials":576,"activeCount":73},[],{"trials":578,"activeCount":73},[],{"trials":580,"activeCount":73},[],{"trials":582,"activeCount":73},[],{"trials":584,"activeCount":73},[],{"trials":586,"activeCount":73},[587],{"nctId":588,"briefTitle":589,"status":246,"phases":590,"primaryCompletion":591,"completion":592,"start":250,"enrollment":593,"conditions":594,"interventions":596},"NCT02339441","Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis",[],"2015-12","2016-03",320,[595],"Early Diffuse Cutaneous Systemic Sclerosis",[573,597,598],"Mycophenolate mofetil","Cyclophosphamide",{"intervention":597,"totalTrials":69,"cells":600},{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":607,"PHASE4":609,"NA":611},{"trials":602,"activeCount":73},[],{"trials":604,"activeCount":73},[],{"trials":606,"activeCount":73},[],{"trials":608,"activeCount":73},[],{"trials":610,"activeCount":73},[],{"trials":612,"activeCount":73},[613],{"nctId":588,"briefTitle":589,"status":246,"phases":614,"primaryCompletion":591,"completion":592,"start":250,"enrollment":593,"conditions":615,"interventions":616},[],[595],[573,597,598],{"intervention":598,"totalTrials":69,"cells":618},{"EARLY_PHASE1":619,"PHASE1":621,"PHASE2":623,"PHASE3":625,"PHASE4":627,"NA":629},{"trials":620,"activeCount":73},[],{"trials":622,"activeCount":73},[],{"trials":624,"activeCount":73},[],{"trials":626,"activeCount":73},[],{"trials":628,"activeCount":73},[],{"trials":630,"activeCount":73},[631],{"nctId":588,"briefTitle":589,"status":246,"phases":632,"primaryCompletion":591,"completion":592,"start":250,"enrollment":593,"conditions":633,"interventions":634},[],[595],[573,597,598]]